adaptive biotechnologies stock news

Engages in the development of an immune medicine platform. Ad Our Strong Buys Double the SP.

Adaptive Biotechnologies Stock Soars 90 After Ringing Nasdaq Opening Bell Following 300m Ipo Geekwire

Adaptive Biotechnologies NASDAQADPT - Get Rating had its price objective dropped by stock analysts at The Goldman Sachs Group from 1400 to 1000 in a research note issued on Tuesday Stock Target Advisor reportsThe brokerage presently has a neutral rating on the stock.

. Stay up to date on the latest stock price chart news analysis fundamentals trading. Based On Fundamental Analysis. Adaptive Biotechnologies Corp - Stock News ADPT Morningstar Rating Rating as of May 13 2022.

It harnesses the inherent biology of the adaptive immune system. 1 hour ago0405 Earnings Flash ADPT ADAPTIVE BIOTECHNOLOGIES annonce un chiffre daffaires de 386 millions de dollars au premier trimestre contre une estimation de 377 millions de dollars par la Bourse. 5 hours agoGoldman Sachs maintains Adaptive Biotechnologies NASDAQADPT with a Neutral and lowers the price target from 14 to 10.

Since then ADPT shares have decreased by 664 and is now trading at 723. The stock has traded between 754 and 792 so far today. Get Adaptive Biotechnologies Corp ADPTNASDAQ real-time stock quotes news price and financial information from CNBC.

Real time Adaptive Biotechnologies Corporation ADPT stock price quote stock graph news analysis. Quote Stock Analysis News Price. Find real-time ADPT - Adaptive Biotechnologies Corp stock quotes company profile news and forecasts from CNN Business.

Stock Market News - Financial News - MarketWatch. Find the latest Adaptive Biotechnologies Corporation ADPT stock quote history news and other vital information to help you with your stock trading and investing. Adaptive Biotechnologies stock was trading at 2152 on March 11th 2020 when COVID-19 Coronavirus reached pandemic status according to the World Health Organization.

Ad Access Stocks in VR Drones Space Wearables Smart Buildings Autonomous Vehicles. Watch Adaptive Biotechnologies. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive.

The Goldman Sachs Groups price objective points to a potential upside of 3298. Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven. Get the latest news and real-time alerts from Adaptive Biotechnologies Corporation ADPT stock at Seeking Alpha.

Press Releases Events Presentations. Robins sold 4424 shares of Adaptive Biotechnologies stock in a transaction on Monday March 7th. Also CEO Chad M.

The shares were sold at an average price of 1201 for a total transaction of. So far 981230 shares have traded compared to average volume of 1668221 shares. Zacks Investment Research Upgrades Adaptive Biotechnologies NASDAQADPT to Hold.

Considering analysts have assigned the stock a price target range of 1400-2500 as the low and high respectively we find the trailing 12-month average consensus price target to be 1960. All your life youve worked very hard. Adaptive Biotech launches 8M-share stock offering SA News Tue Jul.

Stock Quote Chart Analyst Coverage Governance. Now its time to make your savings work for you. SEC Filings current News Events.

Click Here to get. BTIG Research lowered their price objective on shares of Adaptive Biotechnologies from 3500 to 3000 and set a buy rating on the stock in a research note on Wednesday February 16th. Get the latest Adaptive Biotechnologies Corporation ADPT stock news and headlines to help you in your trading and investing decisions.

Wall Street predict expect Adaptive Biotechnologies will report losses per share of 0452. View which stocks have been most impacted by COVID-19. Adaptive Biotechnologies brought in sales totaling 3862 million during Q1 according to data provided by Benzinga Pro.

Ad Learn all about ABT and four other Top Dividend Stocks in Zacks Special Dividend Report. Adaptive Biotechnologies Corp ADPT stock is trading at 782 as of 252 PM on Monday May 23 a gain of 011 or 143 from the previous closing price of 771. Adaptive Biotechnologies GAAP EPS of -044 in-line revenue of 386M beats by 089M.

A high-level overview of Adaptive Biotechnologies Corporation ADPT stock. Companies we believe to be the most innovative. 1551 EASTLAKE AVENUE EAST SUITE 200 SEATTLE Washington 98102 United States 1 206 659-0067.

Adaptive Biotechnologies Corporation NASDAQADPTs beta value is holding at 0 while the average true range ATR indicator is currently reading 080. Volume today is light. Adaptive Biotechnologies is reporting earnings from Q4 on February 15.

MOON is designed to include 50 US. Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15 2022 01-24-2022 at 405 PM EST Adaptive Biotechnologies Announces Preliminary Unaudited 2021 Revenue Results and CFO Transition.

Adaptive Biotechnologies To Lay Off 12 Of Its Workforce Names Tycho Peterson As Cfo Markets Insider

Big Debut Shares Of Adaptive Biotechnologies Rise 100 On First Day As Public Company Geekwire

Adaptive Biotechnologies Corp Shares Fall 6 2 Below Previous 52 Week Low Market Mover Nasdaq

Adaptive Biotechnologies Good Buy For Long Term Investors Adpt Seeking Alpha

Bears Are Losing Control Over Adaptive Biotechnologies Adpt Here S Why It S A Buy Now

How Many Adaptive Biotechnologies Corporation Nasdaq Adpt Shares Do Institutions Own

Our First Assessment On Adaptive Biotechnologies Stock Nasdaq Adpt Seeking Alpha

Adaptive Biotechnologies Stock Soars 90 After Ringing Nasdaq Opening Bell Following 300m Ipo Geekwire

Adaptive Biotechnologies Adpt Reports Q1 Loss Lags Revenue Estimates Nasdaq

Adaptive Biotechnologies Nasdaq Adpt Shareholders Incur Further Losses As Stock Declines 4 1 This Week Taking One Year Losses To 54 Nasdaq

Insiders Of Adaptive Biotechnologies Corporation Nasdaq Adpt Must Have Made A Tidy Sum After Selling Stock Currently Worth Us 35 34 At Us 39 64 Nasdaq